Immunexpress Belgium SRL
Immunexpress Belgium reported total assets of 315,946 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jan 2026).
The score of Immunexpress Belgium shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Immunexpress Belgium's annual accounts
| 2025 | |
|---|---|
| Net result | −305,459 € |
| Equity | −295,459 € |
| Cash | 208,916 € |
| EBITDA | −305,446 € |
| Total assets | 315,946 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 31 Jan 2026
Immunexpress Belgium's financial analysis
- Solvency-93.5%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Immunexpress Belgium
Immunexpress Belgium's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1011.641.704
- VAT number
- BE1011641704
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 16 Jul 2024
- Registered office
- 3018 Leuven
- Latest accounts
- 2025 · filed on 31 Jan 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Immunexpress Belgium (SRL) has been based in Leuven since 2024, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of 305,459 € and equity of −295,459 €; its revenue is not published. Its solvency stands at -93.5%, below the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Immunexpress Belgium
Companies in the same business, of comparable size and area, outside its group.
- VH Ophthalmics Manufacture of medical and dental instruments and supplies Leuven · balance sheet €1.02m
- Hellma Benelux Manufacture of instruments and appliances for measuring, testing and navigation Beveren-Kruibeke-Zwijndrecht · balance sheet 410,163 €
- Benetec Manufacture of medical and dental instruments and supplies Retie · balance sheet €4.28m
- Verachtert Digital Manufacture of medical and dental instruments and supplies Antwerp · balance sheet €1.08m
- Materialise Motion Manufacture of instruments and appliances for measuring, testing and navigation Beringen · balance sheet €2.27m
- Hillrom Belgium Manufacture of medical and dental instruments and supplies Braine-l'Alleud · balance sheet €2.21m
- MY®Health Manufacture of basic pharmaceutical products Lummen · balance sheet €2.56m
- Adler Ortho Belgium Manufacture of medical and dental instruments and supplies Brussels · balance sheet €2.71m
Frequently asked questions about Immunexpress Belgium
What is the revenue of Immunexpress Belgium?
Immunexpress Belgium files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Immunexpress Belgium?
In Belgium, the VAT number is the company number prefixed with BE: BE1011641704 for Immunexpress Belgium, if the company is VAT-registered. Its company number (CBE) is 1011.641.704.
Where is the registered office of Immunexpress Belgium?
According to the CBE register, the registered office of Immunexpress Belgium is in 3018 Leuven.
What is the equity of Immunexpress Belgium?
At the close of the 2025 financial year, the equity of Immunexpress Belgium amounts to -295,459 €, a solvency of -93.5% of total assets.
Who manages Immunexpress Belgium?
The register lists 1 active mandates at Immunexpress Belgium. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Immunexpress Belgium
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →